UNIVERSITY OF ILLINOIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.illinois.edu

Clinical Trials

A Weight-Loss Program in Helping Obese Black Women Lose Weight

Phase 3

Conditions: Breast Cancer
Obesity
Weight Changes

First Posted Date: 2009-03-11

Last Posted Date: 2013-12-18

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 200

Registration Number: NCT00859989

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis (NASH)
Hepatic Steatosis

Interventions: Drug: Placebo
Drug: Omega-3-acid ethyl esters (Lovaza)

First Posted Date: 2009-02-18

Last Posted Date: 2013-07-24

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 12

Registration Number: NCT00845845

Locations: 🇺🇸
The University of Illinois Chicago, Chicago, Illinois, United States

The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery

Terminated

Conditions: Atrial Fibrillation

First Posted Date: 2009-02-18

Last Posted Date: 2014-04-23

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 100

Registration Number: NCT00846534

Locations: 🇺🇸
Advocate Christ Medical Center, Oak Lawn, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries

Not Applicable

Completed

Conditions: Chronic Illness
Medication Errors
Elderly Patients
Adverse Effects

Interventions: Behavioral: Enhanced medication therapy management
Behavioral: Basic medication therapy management

First Posted Date: 2008-10-16

Last Posted Date: 2019-07-24

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 637

Registration Number: NCT00773942

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Health System, Durham, North Carolina, United States
🇺🇸
Baylor Health Care System, Dallas, Texas, United States

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Dietary Supplement: soy protein isolate
Other: placebo

First Posted Date: 2008-10-03

Last Posted Date: 2013-09-20

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 284

Registration Number: NCT00765479

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

Duragen Versus Duraguard in Chiari Surgery

Phase 3

Completed

Conditions: Chiari Malformation

Interventions: Procedure: Duragen duraplasty
Procedure: Duraguard duraplasty

First Posted Date: 2008-08-26

Last Posted Date: 2015-07-13

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 34

Registration Number: NCT00741858

Locations: 🇺🇸
University of Illinois Medical Center in Chicago, Chicago, Illinois, United States

Lucentis for New Onset Neovascular Glaucoma

Phase 1

Withdrawn

Conditions: Neovascular Glaucoma
New Onset Glaucoma
Glaucoma
New Onset Neovascular Glaucoma

Interventions: Drug: Ranibizumab (Lucentis)

First Posted Date: 2008-08-01

Last Posted Date: 2020-02-17

Lead Sponsor: University of Illinois at Chicago

Registration Number: NCT00727038

Polestriding Versus Walking for Subjects With Poor Leg Circulation

Phase 2

Completed

Conditions: Peripheral Arterial Disease

Interventions: Behavioral: Walking with poles
Behavioral: Walking exercise

First Posted Date: 2008-07-21

Last Posted Date: 2013-02-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 146

Registration Number: NCT00719355

Locations: 🇺🇸
Edward Hines Jr. VA Hospital, Hines, Illinois, United States

Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

Phase 4

Completed

Conditions: Retinal Degenerations

Interventions: Drug: 2% dorzolamide

First Posted Date: 2008-07-16

Last Posted Date: 2021-10-29

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 44

Registration Number: NCT00716586

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

Emend for Multiple-day Emetogenic Chemotherapy

Phase 2

Completed

Conditions: Nausea
Vomiting

Interventions: Drug: aprepitant, ondansetron, dexamethasone

First Posted Date: 2008-07-09

Last Posted Date: 2021-08-04

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 22

Registration Number: NCT00711555

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy